Showing 2981-2990 of 5646 results for "".
- Prevent Blindness Offers New Resources for Education and to Raise Awareness for Stargardt Diseasehttps://modernod.com/news/prevent-blindness-offers-new-resources-for-education-and-to-raise-awareness-for-stargardt-disease/2482289/Prevent Blindness has created new educational materials on Stargardt disease. Coinciding with May’s" IRD Genetic Testing Awareness Month," Prevent Blindness now offers a dedicated web page, fact sheets, a new 'Focus on Eye Health Expert Series' episode, and
- Clearside Biomedical Publishes Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS) Injectionhttps://modernod.com/news/clearside-biomedical-publishes-consensus-guidelines-for-drug-delivery-via-suprachoroidal-space-scs-injection/2482288/Clearside Biomedical announced that new guidelines that represent best practices for injection into the suprachoroidal space have been published in "RETINA, The Journal of Retinal and Vitreous Diseases." The publication, entitled, “Suprachoroidal Space Injection Techniqu
- Bausch + Lomb Launches Zenlens Echo Scleral Lenses in the United Stateshttps://modernod.com/news/bausch-lomb-launches-zenlens-echo-scleral-lenses-in-the-united-states/2482272/Bausch + Lomb announced the US launch of Zenlens Echo, a non-prosthetic, custom scleral contact lens. The Echo is designed to fit a wide variety of corneal shapes and sizes, including patients who have advanced ocular conditions such as corneal degeneration and certain postoperative con
- Johnson & Johnson to Debut EYE-RD Global Registry at ARVOhttps://modernod.com/news/johnson-johnson-to-debut-eye-rd-global-registry-at-arvo/2482261/Johnson & Johnson announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024. The company's two oral presentations wil
- BVI’s Podeye Hydrophobic Monofocal IOL Launched in Japanhttps://modernod.com/news/bvis-podeye-hydrophobic-monofocal-iol-launched-in-japan/2482239/BVI Medical announced the launch of the Podeye hydrophobic monofocal intraocular lenses (IOL) in Japan after receiving approval by the Japanese Pharmaceuticals and Medical Devices Agency. Podeye is now available for commercial use and available to surgeons across the country. The Podeye
- False Claims Act Complaint Filed Against Regeneron for Fraudulent Drug Pricing Reportinghttps://modernod.com/news/false-claims-act-complaint-filed-against-regeneron-for-fraudulent-drug-pricing-reporting/2482228/The US Department of Justice (DOJ) has filed a complaint under the False Claims Act (FCA) against Regeneron alleging that the company fraudulently inflated Medicare reimbursement rates for Eylea (aflibercept) by knowingly submitting false average sales price reports to CMS that excluded
- Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating Aqueous Outflow Restorative Procedure with OMNIhttps://modernod.com/news/sight-sciences-announces-the-publication-of-large-scale-real-world-migs-study-demonstrating-aqueous-outflow-restorative-procedure-with-omni/2482226/Sight Sciences announced the results as published in the American Journal of Ophthalmology (AJO) International of a large scale, comparative real-world clinical outcomes study of patients treated by three leading, minimally invasive glaucoma surgery (MIGS) technologies.
- Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase 2 Trialshttps://modernod.com/news/qlaris-bios-novel-iop-lowering-product-qls111-is-dosed-in-phase-2-trials/2482195/Qlaris Bio announced the initiation and dosing of two separate US phase 2 masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma. “The start of these phase 2 trials represents a key milestone in our goal of bringing QLS‑111
- Lenz Therapeutics Completes Merger with Graphite Bio; Debuts on Nasdaqhttps://modernod.com/news/lenz-therapeutics-completes-merger-with-graphite-bio-to-debut-on-nasdaq/2482177/Lenz Therapeutics announced the completion of its previously announced merger with Graphite Bio. The new combined company will operate under the name Lenz Therapeutics and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. &ldquo
- OcuTerra Fails Phase 2 DR:EAM Trial Evaluating Nesvategrast for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-fails-phase-2-dream-trial-evaluating-nesvategrast-for-diabetic-retinopathy/2482163/OcuTerra Therapeutics announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast (OTT166), a novel, selective RGD integrin inhibitor developed as an eye drop. The clinical trial did not meet its primary or key secondary ef